Shenzhen Hosts Third Stop of 2025 China Biotech Overseas Financing Training Series at Bay Gravity

After weathering the setbacks faced by Chinese pharmaceutical companies in their overseas expansion in 2022, the past two years have marked a harvest period for Chinese innovative drugs going global. For China’s innovative drug industry as a whole, this represents a shift from a previous focus on license-in deals to a current emphasis on license-out transactions. Underpinning this change is the evolving role of Chinese innovative drug assets in the global market. According to data from Guosheng Securities,FromFrom 2019 to 2023, among domestic BD transaction assignees, the proportion of MNCs increased from 14% to 36%, while the share of overseas biotech companies also rose from 14% to 35%, nearly matching that of MNCs.For China’s innovative drug industry as a whole, the focus has shifted from predominantly license-in deals in the past to primarily license-out transactions today. Underlying this shift is the changing role of Chinese innovative drug assets in the global market.

Chinese innovative drug assets are not merely a “procurement” channel for overseas biotech firms; some have even helped these companies secure financing and stage a comeback. Chinese innovative drugs are now influencing the financing wave among U.S.-listed biotech firms.

Currently, multinational corporations (MNCs), US dollar funds, as well as domestic funds and local pharmaceutical companies, are actively exploring opportunities for overseas financing transactions!

Global expansion is a tidal wave, but with “strong winds and high waves,” companies must make thorough preparations to “escort” their overseas ventures and cope withLack of systemic understanding of the entire cross-border fundraising process, frequent legal and intellectual property issues, misalignment between pipeline design and international clinical standards, and dual pressures from funding and policy environmentsand other core issues. To this end, VCBeat and Niukou Capital have launched a series ofChinaPractical Training on Overseas Financing for Biotech Companies, on March 27 this year, the first session of 2025 was successfully held at the Haixing Pharmaceutical and Health Innovation Park in Haidian District, Beijing; on May 12–13, the second session was successfully hosted by the Suzhou Bohe Innovation Center! FromEnd-to-End Practical Guide to Overseas Fundraising, Legal and Regulatory Risks, Taxation, and Intellectual Property,MNC Project Selection Criteria and Clinical Design StrategiesThrough sharing practical experience and case studies from multiple perspectives, we help biotech companies establish a faster and more stable foothold overseas, thereby achieving the internationalization of their products and technologies.May 29-30, Shenzhen · Bay Attraction, the third training session officially launched!

Phase I On-site

Phase II On-Site

Niu Capital and enterprises implementing the NewCo model will provide an in-depth analysis of the “origins and evolution” of the NewCo model, and share practical insights on its implementation through real-world case studies.

This training will analyze the strategic layout and cooperation needs of multinational corporations (MNCs) from the perspective of demand-side stakeholders, while interpreting the investment preferences and decision-making processes of USD-denominated funds. Enterprises will have the opportunity to engage directly with potential partners to understand their expectations and concerns, thereby enhancing the success rate of fundraising.

Leading law firms and tax experts will be present on-site to provide guidance, covering key aspects of legal compliance, contract terms, international tax regulations, intellectual property protection, and risk mitigation in cross-border transactions. This support aims to fortify the legal safeguards for enterprises, ensuring a smooth and unimpeded financing process.

The training program specially features an industry networking dinner with structured open-discussion sessions, offering participants the opportunity to engage in-depth with industry leaders, peer elites, and potential partners, thereby broadening their horizons and fostering more extensive collaborative relationships.